11.75% Vaccine Reverse Convertible Bond – available on secondary market

11.75% Vaccine Reverse Convertible Bond – available on secondary market

2-year term, fixed annual interest rate of 11.75% and a barrier being set at 55% of BioNTech and Moderna

Advertisement

The 11.75% Vaccine Reverse Convertible Bond combines two fixed interest payments of 11.75% with a partial safety mechanism for the invested capital down to the barrier of 55%. The interest amount is paid out annually, regardless of the performance of the two underlying (BioNTech SE and Moderna, Inc.).

The share basket of the Reverse Convertible Bond consists of two pharmaceutical companies, successfully launching a vaccine against COVID-19 on the market: 

  • BioNTech SE is a German biotechnology company listed on the stock exchange since the end of 2019. Biontech's focus is on mRNA-based drug discovery. As of early 2020, Biontech developed the BNT162b2 vaccine against the human coronavirus SARS-CoV-2, which will be packaged at Pfizer facilities for global use. 

  • Moderna, Inc. is a U.S. biotechnology company that specializes in the research and development of mRNA-based drugs. The company's CoV vaccine is also based on this technology and, like Pfizer's, has been shown to provide a high level of protection against infection. 

If the daily closing prices of the two underlying shares (BioNTech SE and Moderna, Inc.) always quote above the respective barrier of 55% during the observation period, or if the closing prices of each shares quote at or above their respective strike at the final valuation date, the certificate is redeemed at 100% of the nominal value. 
Otherwise, physical delivery of the share with the lowest performance is effected. 

The issue price amounts to 100 % (nominal value EUR 1,000) within the subscription period. Further information as well as the Key Information Document please find on Product Page.

Reverse Convertible Bonds - explained in an easy way

Please adjust your cookie settings to allow YouTube videos or start the video here: External link to the video on YouTube

For any additional information you may require do not hesitate to contact us on +43 1 515 20-484.

The Team Structured Products of Raiffeisen Centrobank

 

 

 

Back
Previous News
Next News
Key facts:
  • Name: 11,75 % Impfstoff Aktienanleihe
  • ISIN: AT0000A2RZF6
  • Initial valuation date: Aug 03, 2021
  • Term: 0.5 years
    (Maturity date: Aug 04, 2023)
  • Listing: Vienna, Frankfurt, Stuttgart
Product PageProduct Folder
Disclaimer
This is advertising. This non-binding information does not constitute advice, recommendation or invitation to conclude a transaction. The presentation is of a generic nature, does not take into account the personal circumstances of potential investors and therefore cannot replace individual investor and investment-oriented advice and risk disclosure. This advertisement has not been prepared in compliance with the legal provisions promoting the independence of investment research and is not subject to the ban on trading following the dissemination of investment research. A base prospectus (including any supplements) that complies with the Austrian Capital Market Act and has been approved by the competent authorities (CSSF, FMA) is available on the website of Raiffeisen Bank International AG (raiffeisencertificates.com/en/securities-prospectus/). The approval of the base prospectus by the competent authorities is not to be understood as an endorsement by the competent authorities of the financial instruments described herein. We recommend reading the prospectus before making an investment decision. Important additional information on the products described (in particular their opportunities and risks) can be found on the website of Raiffeisen Bank International AG at raiffeisencertificates.com/en/; in particular, the approved base prospectus (including any supplements) can be found at (raiffeisencertificates.com/en/securities-prospectus/) and under "Customer Information and Regulatory Issues" at raiffeisencertificates.com/en/customer-information/. Regulatory authorities: Austrian Financial Market Authority (FMA), European Central Bank (ECB). Imprint according to Austrian media law: Media owner and producer is Raiffeisen Bank International AG, Am Stadtpark 9, 1030 Vienna/Austria.